Manufacturer's ref.No: (b)(4).Since no device has been received for analysis, no product investigation can be performed, and the customer complaint cannot be confirmed.Manufacturer record evaluation cannot be conducted because the no lot number was provided by the customer.If information is obtained that was not available for the initial report, a follow-up report will be filed as appropriate.If additional information is received regarding this event, a supplemental 3500a report will be submitted to the fda.Biosense webster manufacturer's report numbers: 2029046-2021-00664, 2029046-2021-00665, 2029046-2021-00667, 2029046-2021-00668, 2029046-2021-00669, and 2029046-2021-00670 are related to the same incident.
|
This complaint is from a literature source.The following complications were reported in this publication: group 1 ( less than or equal to 2 pulmonary vein isolations ).It was reported that 2 patients from the group undergoing less than or equal to 2 pulmonary vein isolations underwent catheter ablation of atrial fibrillation and suffered pericardial effusion requiring drainage.Model and catalog number are not available, but the suspected device is navi-star.Other biosense webster devices that were also used in this study: 10-pole lasso non-biosense webster devices that were also used in this study: chilli, acunav.Publication details: title: predictors of success after selective pulmonary vein isolation of arrhythmogenic pulmonary veins for treatment of atrial fibrillation.Objective: the purpose of this study was to identify a subgroup of patients undergoing af ablation with good clinical success after limited pv isolation.Methods: patients (n= 450) underwent trigger-guided segmental isolation of only arrhythmogenic pvs.We compared clinical characteristics of patients who required isolation of only one or two pvs to those in whom af ablation required isolating greater then/equal to 3 pvs.
|